scholarly journals Risk profile, management, and outcomes of patients with venous thromboembolism attended in Spanish Emergency Departments

Medicine ◽  
2017 ◽  
Vol 96 (48) ◽  
pp. e8796 ◽  
Author(s):  
Sonia Jimenez ◽  
Pedro Ruiz-Artacho ◽  
Marta Merlo ◽  
Coral Suero ◽  
Albert Antolin ◽  
...  
2010 ◽  
Vol 29 (4) ◽  
pp. 282-287 ◽  
Author(s):  
Jovan Antović

»Point-of-Care« D-Dimer TestingD-dimer testing is efficient in the exclusion of venous thromboembolism (VTE). D-dimer laboratory assays are predominantly performed in centralised laboratories in intra-hospital settings although most patients with suspected VTE are presented in primary care. On the other hand decreasing turnaround time for laboratory testing may significantly improve efficacy in emergency departments. Therefore an introduction of a rapid, easy to perform point of care (POC) assay for the identification of D-dimer may offer improvement in diagnostics flow of VTE both in primary care and emergency departments while it could also improve our diagnostic possibilities in some other severe clinical conditions (e.g. disseminated intra-vascular coagulation (DIC) and aortic aneurism (AA)) associated with increased D-dimer. Several POC D-dimer assays have been evaluated and majority of them have met the criteria for rapid and safe exclusion of VTE. In our hands three assays (Stratus, Pathfast and Cardiac) have the laboratory performance profile comparable with our routine D-dimer laboratory assay (Tinaqaunt).


2008 ◽  
Vol 15 (3) ◽  
pp. 289-296 ◽  
Author(s):  
Faisal Al Sayegh ◽  
Wael Almahmeed ◽  
Salah Al Humood ◽  
Mahmoud Marashi ◽  
Ahmed Bahr ◽  
...  

2011 ◽  
Vol 105 (02) ◽  
pp. 221-231 ◽  
Author(s):  
Elvira Grandone ◽  
Maurizio Margaglione

SummaryResults from epidemological studies are consistent with the hypothesis that disparities in venous thromboembolism (VTE) burden are attributable to differences in genetic structure among populations from different genetic backgrounds. To that end, recent genetic studies have demonstrated not only potential associations between certain alleles and VTE but also clear differences in the distribution of these alleles in patients stratified by ancestry. There are a number of notable clinical and pathophysiological questions that arise from these findings. First at all is defining the precise variant(s) that alter disease susceptibility. The comparatively lower rates of VTE recorded among Asians would imply that risk profile is devoid of many risk factors on comparison to Caucasian or African counterparts or that a putative protective factor is advocated in the former population. Identification of these variants provided specific insight into VTE disease in selected populations and also shed lights on the biology of the disease. The association observed between ancestry and VTE is likely to be multifactorial, possibly reflecting, in addition to genetic variation, also socioeconomic differences. Acknowledgment of this may provide useful information in biomedical contexts and help to identify individual risk factors for VTE.


2021 ◽  
Vol 78 (19) ◽  
pp. B112
Author(s):  
Ahmed El Shaer ◽  
Akram Kawsara ◽  
Abdul Hakim Almakadma ◽  
Amani Khalouf ◽  
Mohamad Alkhouli

Pituitary ◽  
2012 ◽  
Vol 16 (2) ◽  
pp. 175-181 ◽  
Author(s):  
S. Koutroumpi ◽  
V. Daidone ◽  
M. T. Sartori ◽  
M. G. Cattini ◽  
N. M. Albiger ◽  
...  

Phlebologie ◽  
2017 ◽  
Vol 46 (05) ◽  
pp. 288-291
Author(s):  
P. Prandoni

SummaryOnce anticoagulation is stopped, the risk of recurrent venous thromboembolism (VTE) over years approaches 40 % of all patients with a first episode of VTE. The risk is twice as high in patients with unprovoked VTE than in those with minor (either transient or persistent) risk factors of thrombosis. Although the latest international guidelines suggest indefinite anticoagulation for most patients with a first episode of unprovoked VTE, strategies that incorporate the assessment of residual vein thrombosis and D-dimer have the potential to identify a substantial proportion of subjects in whom anticoagulation can be safely discontinued. For those patients in whom anticoagulation cannot be discontinued, new opportunities are offered by the availability of low-dose anti-Xa compounds, which have been found to possess an extremely favorable benefit/risk profile.


Sign in / Sign up

Export Citation Format

Share Document